{"DataElement":{"publicId":"3607996","version":"1","preferredName":"Dose Limiting Toxicity","preferredDefinition":"Toxicity type that makes it impossible to escalate the dosage of a therapy agent/measure._A position on a scale of intensity or amount or quality for dose limiting toxicity.","longName":"2184272v1.0:3607993v1.0_360798","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2012911","version":"3","preferredName":"Dose Limiting Toxicity","preferredDefinition":"Toxicity type that makes it impossible to escalate the dosage of a therapy agent/measure.","longName":"DOSE_LIMT_TOX","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2206422","version":"1","preferredName":"Dose Limited","preferredDefinition":"The amount of medicine taken, or radiation given, at one time.:No value exists.","longName":"C25488:CL110648","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Limited","conceptCode":"CL110648","definition":"No value exists.","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-F49E-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177313","version":"1","preferredName":"Toxicity","preferredDefinition":"Toxicity; the degree to which something is poisonous.","longName":"Toxicity","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Toxicity","conceptCode":"C27990","definition":"The finding of bodily harm due to the poisonous effects of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-52C7-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008573","version":"1","preferredName":"Adverse Event Results","preferredDefinition":"the outcome or resolution of the patient's adverse events.","longName":"AE_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB869948-5E78-2537-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-04-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-04-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B03275-E35F-61A3-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-07-26","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3607987","version":"1","preferredName":"Adverse Event Worst Grade","preferredDefinition":"A position on a scale of intensity or amount or quality for dose limiting toxicity.","longName":"3607987v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Greater than or equal to Grade 3 non-hematologic toxicity, not an expected toxicity of Cis-Etop regimen, specify","valueDescription":"Negation Hematologic Severe Adverse Event","ValueMeaning":{"publicId":"3607988","version":"1","preferredName":"Negation Hematologic Severe Adverse Event","longName":"3607988","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: Pertaining to or related to the blood and blood-forming organs.: Severe adverse event is an experience that requires therapeutic intervention and interrupts busual daily activities. See NCI Common Terminology Criteria for Adverse Events.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hematologic","conceptCode":"C62780","definition":"Pertaining to or related to the blood and blood-forming organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Severe Adverse Event","conceptCode":"C41340","definition":"An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBA4A7CC-86A4-5D6F-E040-BB89AD43026D","latestVersionIndicator":"Yes","beginDate":"2012-10-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CBA4A7CC-86BD-5D6F-E040-BB89AD43026D","beginDate":"2012-10-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-10-09","modifiedBy":"ONEDATA","dateModified":"2012-10-09","deletedIndicator":"No"},{"value":"Grade 4 anemia","valueDescription":"Life Threatening or Disabling Adverse Event Anemia","ValueMeaning":{"publicId":"3607989","version":"1","preferredName":"Life Threatening or Disabling Adverse Event Anemia","longName":"3607989","preferredDefinition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: A reduction in the number of red blood cells per cu mm, the amount of hemoglobin in 100 ml of blood, and the volume of packed red blood cells per 100 ml of blood. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Life Threatening or Disabling Adverse Event","conceptCode":"C41337","definition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Anemia","conceptCode":"C2869","definition":"A reduction in the number of red blood cells, the amount of hemoglobin, and/or the volume of packed red blood cells. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBA4A7CC-86CA-5D6F-E040-BB89AD43026D","latestVersionIndicator":"Yes","beginDate":"2012-10-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CBA4A7CC-86E3-5D6F-E040-BB89AD43026D","beginDate":"2012-10-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-10-09","modifiedBy":"ONEDATA","dateModified":"2012-10-09","deletedIndicator":"No"},{"value":"Grade 4 thrombocytopenia","valueDescription":"Life Threatening or Disabling Adverse Event Thrombocytopenia","ValueMeaning":{"publicId":"3607990","version":"1","preferredName":"Life Threatening or Disabling Adverse Event Thrombocytopenia","longName":"3607990","preferredDefinition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: A condition in which there is an abnormally small number of platelets in the circulating blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Life Threatening or Disabling Adverse Event","conceptCode":"C41337","definition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Thrombocytopenia","conceptCode":"C3408","definition":"A laboratory test result indicating that there is an abnormally small number of platelets in the circulating blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBA4A7CC-86F0-5D6F-E040-BB89AD43026D","latestVersionIndicator":"Yes","beginDate":"2012-10-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CBA4A7CC-8709-5D6F-E040-BB89AD43026D","beginDate":"2012-10-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-10-09","modifiedBy":"ONEDATA","dateModified":"2012-10-09","deletedIndicator":"No"},{"value":"Grade 4 neutropenia","valueDescription":"Life Threatening or Disabling Adverse Event Neutrophil Count Decreased","ValueMeaning":{"publicId":"3607991","version":"1","preferredName":"Life Threatening or Disabling Adverse Event Neutrophil Count Decreased","longName":"3607991","preferredDefinition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: A decrease in the number of neutrophils in the peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Life Threatening or Disabling Adverse Event","conceptCode":"C41337","definition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neutropenia","conceptCode":"C80520","definition":"A decrease in the number of neutrophils in the peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBA4A7CC-8716-5D6F-E040-BB89AD43026D","latestVersionIndicator":"Yes","beginDate":"2012-10-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CBA4A7CC-872F-5D6F-E040-BB89AD43026D","beginDate":"2012-10-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-10-09","modifiedBy":"ONEDATA","dateModified":"2012-10-09","deletedIndicator":"No"},{"value":"Grade 3 neutropenia with persisent fever (febrile neutropenia) for more than 7 days","valueDescription":"Severe Adverse Event Neutropenic Fever","ValueMeaning":{"publicId":"3607992","version":"1","preferredName":"Severe Adverse Event Neutropenic Fever","longName":"3607992","preferredDefinition":"Severe adverse event is an experience that requires therapeutic intervention and interrupts busual daily activities. See NCI Common Terminology Criteria for Adverse Events.: Neutropenia associated with fever, the latter indicating the presence of an infection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Severe Adverse Event","conceptCode":"C41340","definition":"An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Febrile Neutropenia","conceptCode":"C35665","definition":"Neutropenia associated with fever, the latter indicating the presence of an infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBA4A7CC-873C-5D6F-E040-BB89AD43026D","latestVersionIndicator":"Yes","beginDate":"2012-10-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CBA4A7CC-8755-5D6F-E040-BB89AD43026D","beginDate":"2012-10-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-10-09","modifiedBy":"ONEDATA","dateModified":"2012-10-09","deletedIndicator":"No"},{"value":"Grade 3 diarrhea lasting for more than 72 hours despite optimal medical management","valueDescription":"Severe Adverse Event Diarrhea","ValueMeaning":{"publicId":"4420596","version":"1","preferredName":"Severe Adverse Event Diarrhea","longName":"4420596","preferredDefinition":"An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.: Watery bowel movements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Severe Adverse Event","conceptCode":"C41340","definition":"An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Diarrhea","conceptCode":"C2987","definition":"Watery bowel movements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-4FB1-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-4FCA-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 3 vomiting lasting for more than 72 hours despite optimal medical management","valueDescription":"Severe Adverse Event Vomiting","ValueMeaning":{"publicId":"4420597","version":"1","preferredName":"Severe Adverse Event Vomiting","longName":"4420597","preferredDefinition":"An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.: Forceful ejection of the contents of the stomach through the mouth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Severe Adverse Event","conceptCode":"C41340","definition":"An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Vomiting","conceptCode":"C3442","definition":"Forceful ejection of the contents of the stomach through the mouth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-4FD7-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-4FF0-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 3 nausea lasting for more than 72 hours despite optimal medical management","valueDescription":"Severe Adverse Event Nausea","ValueMeaning":{"publicId":"4420598","version":"1","preferredName":"Severe Adverse Event Nausea","longName":"4420598","preferredDefinition":"An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.: Upper abdominal discomfort associated with an urge to vomit.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Severe Adverse Event","conceptCode":"C41340","definition":"An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Nausea","conceptCode":"C3258","definition":"Upper abdominal discomfort associated with an urge to vomit.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-4FFD-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-5016-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 3+ non-hematological toxicity","valueDescription":"Grade 3+ non-hematological toxicity","ValueMeaning":{"publicId":"4420599","version":"1","preferredName":"Grade 3+ non-hematological toxicity","longName":"4420599","preferredDefinition":"Grade 3+ non-hematological toxicity","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-5020-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-5039-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 4 hypophosphatemia with life-threatening consequence","valueDescription":"Life Threatening or Disabling Adverse Event Hypophosphatemia","ValueMeaning":{"publicId":"4420600","version":"1","preferredName":"Life Threatening or Disabling Adverse Event Hypophosphatemia","longName":"4420600","preferredDefinition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: Lower than normal levels of phosphates in the circulating blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Life Threatening or Disabling Adverse Event","conceptCode":"C41337","definition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hypophosphatemia","conceptCode":"C37977","definition":"Lower than normal levels of phosphates in the circulating blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-5046-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-505F-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 4 hyponatremia with life-threatening consequence","valueDescription":"Life Threatening or Disabling Adverse Event Hyponatremia","ValueMeaning":{"publicId":"4420601","version":"1","preferredName":"Life Threatening or Disabling Adverse Event Hyponatremia","longName":"4420601","preferredDefinition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: Lower than normal levels of sodium in the circulating blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Life Threatening or Disabling Adverse Event","conceptCode":"C41337","definition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hyponatremia","conceptCode":"C37976","definition":"Lower than normal levels of sodium in the circulating blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-506C-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-5085-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 4 hypomagnesemia with life-threatening consequence","valueDescription":"Life Threatening or Disabling Adverse Event Hypomagnesemia","ValueMeaning":{"publicId":"4420602","version":"1","preferredName":"Life Threatening or Disabling Adverse Event Hypomagnesemia","longName":"4420602","preferredDefinition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: Lower than normal levels of magnesium in the circulating blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Life Threatening or Disabling Adverse Event","conceptCode":"C41337","definition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hypomagnesemia","conceptCode":"C37975","definition":"Lower than normal levels of magnesium in the circulating blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-5092-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-50AB-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 4 hypokalemia with life-threatening consequence","valueDescription":"Life Threatening or Disabling Adverse Event Hypokalemia","ValueMeaning":{"publicId":"4420603","version":"1","preferredName":"Life Threatening or Disabling Adverse Event Hypokalemia","longName":"4420603","preferredDefinition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: Lower than normal levels of potassium in the circulating blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Life Threatening or Disabling Adverse Event","conceptCode":"C41337","definition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hypokalemia","conceptCode":"C37974","definition":"Lower than normal levels of potassium in the circulating blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-50B8-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-50D1-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 3-4 hypophosphatemia lasting longer than 72 hours despite active replacement","valueDescription":"Hypophosphatemia","ValueMeaning":{"publicId":"2751402","version":"1","preferredName":"Hypophosphatemia","longName":"2751402","preferredDefinition":"Hypophosphatemia; lower than normal levels of phosphates in the circulating blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypophosphatemia","conceptCode":"C37977","definition":"Lower than normal levels of phosphates in the circulating blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4DC907AE-0AA7-716C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-50E5-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 3-4 hyponatremia lasting longer than 72 hours despite active replacement","valueDescription":"Hyponatremia","ValueMeaning":{"publicId":"4291753","version":"1","preferredName":"Hyponatremia","longName":"4291753","preferredDefinition":"Lower than normal levels of sodium in the circulating blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyponatremia","conceptCode":"C37976","definition":"Lower than normal levels of sodium in the circulating blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8ABEA26-6341-ED7C-E040-BB89AD4312B2","latestVersionIndicator":"Yes","beginDate":"2014-05-05","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-05-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-50F9-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 3-4 hypomagnesemia lasting longer than 72 hours despite active replacement","valueDescription":"Hypomagnesemia","ValueMeaning":{"publicId":"3123624","version":"1","preferredName":"Hypomagnesemia","longName":"3123624","preferredDefinition":"A disorder characterized by laboratory test results that indicate a low concentration of magnesium in the  blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypomagnesemia","conceptCode":"E12333","definition":"A disorder characterized by laboratory test results that indicate a low concentration of magnesium in the  blood.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BC1C923-970D-5F51-E040-BB89AD4331F6","latestVersionIndicator":"Yes","beginDate":"2010-07-19","endDate":null,"createdBy":"CURTIST","dateCreated":"2010-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-510E-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 3-4 hypokalemia lasting longer than 72 hours despite active replacement","valueDescription":"Hypokalemia","ValueMeaning":{"publicId":"3123622","version":"1","preferredName":"Hypokalemia","longName":"3123622","preferredDefinition":"A disorder characterized by laboratory test results that indicate a low concentration of potassium in the  blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypokalemia","conceptCode":"E12327","definition":"A disorder characterized by laboratory test results that indicate a low concentration of potassium in the  blood.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BC1C923-96E8-5F51-E040-BB89AD4331F6","latestVersionIndicator":"Yes","beginDate":"2010-07-19","endDate":null,"createdBy":"CURTIST","dateCreated":"2010-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-5122-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 4 hyperglycemia lasting longer than 24 hours despite active management or any duration with life-threatening consequences","valueDescription":"Life Threatening or Disabling Adverse Event Hyperglycemia","ValueMeaning":{"publicId":"4420604","version":"1","preferredName":"Life Threatening or Disabling Adverse Event Hyperglycemia","longName":"4420604","preferredDefinition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: Abnormally high level of glucose in the blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Life Threatening or Disabling Adverse Event","conceptCode":"C41337","definition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hyperglycemia","conceptCode":"C26797","definition":"Abnormally high level of glucose in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-512F-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-5148-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 3 creatinine lasting longer than 72 hours despite hydration","valueDescription":"Severe Adverse Event Creatinine","ValueMeaning":{"publicId":"4420605","version":"1","preferredName":"Severe Adverse Event Creatinine","longName":"4420605","preferredDefinition":"An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.: The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Severe Adverse Event","conceptCode":"C41340","definition":"An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Creatinine","conceptCode":"C399","definition":"The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-5155-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-516E-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 4 creatinine","valueDescription":"Life Threatening or Disabling Adverse Event Creatinine","ValueMeaning":{"publicId":"4420606","version":"1","preferredName":"Life Threatening or Disabling Adverse Event Creatinine","longName":"4420606","preferredDefinition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Life Threatening or Disabling Adverse Event","conceptCode":"C41337","definition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Creatinine","conceptCode":"C399","definition":"The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-517B-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-5194-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 3-4 bilirubin increased","valueDescription":"Hyperbilirubinemia","ValueMeaning":{"publicId":"4395655","version":"1","preferredName":"Hyperbilirubinemia","longName":"4395655","preferredDefinition":"Abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyperbilirubinemia","conceptCode":"C27088","definition":"Abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEB79BBE-6C13-5F7C-E040-BB89AD435DD5","latestVersionIndicator":"Yes","beginDate":"2014-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-51A8-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 3-4 AST","valueDescription":"SGOT (AST)","ValueMeaning":{"publicId":"2562566","version":"1","preferredName":"SGOT (AST)","longName":"2562566","preferredDefinition":"A family of pyridoxal phosphate-dependent enzymes involved in amino acid metabolism and in the urea and tricarboxylic acid cycles. Aspartate aminotransferase specifically and reversibly catalyzes the transfer of an amino group from L-aspartate to alpha-ketoglutarate forming oxaloacetate and L-glutamate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aspartate Aminotransferase","conceptCode":"C25202","definition":"A family of pyridoxal phosphate-dependent enzymes involved in amino acid metabolism and in the urea and tricarboxylic acid cycles. Aspartate aminotransferase specifically and reversibly catalyzes the transfer of an amino group from L-aspartate to alpha-ketoglutarate forming oxaloacetate and L-glutamate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C173-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-04","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-10-04","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-51BD-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 3-4 ALT","valueDescription":"Grade 3-4 ALT","ValueMeaning":{"publicId":"4420607","version":"1","preferredName":"Grade 3-4 ALT","longName":"4420607","preferredDefinition":"Grade 3-4 ALT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-51C8-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-51E1-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 3-4 GGT","valueDescription":"Gamma-Glutamyl Transpeptidase","ValueMeaning":{"publicId":"3467391","version":"1","preferredName":"Gamma-Glutamyl Transpeptidase","longName":"3467391","preferredDefinition":"GGT participates in the transfer of amino acids across the cellular membrane and in glutathione metabolism. High concentrations are found in the liver, bile ducts, and the kidney.  A test that measures the amount of GGT in the blood is used to detect diseases of the liver, bile ducts, and kidney; and to differentiate liver or bile duct (hepatobiliary) disorders from bone disease. (from http://health.allrefer.com)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gamma-Glutamyl Transpeptidase","conceptCode":"C37959","definition":"GGT participates in the transfer of amino acids across the cellular membrane and in glutathione metabolism. High concentrations are found in the liver, bile ducts, and the kidney.  A test that measures the amount of GGT in the blood is used to detect diseases of the liver, bile ducts, and kidney; and to differentiate liver or bile duct (hepatobiliary) disorders from bone disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C15BE949-4259-41CD-E040-BB89AD4344AF","latestVersionIndicator":"Yes","beginDate":"2012-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-31","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-51F5-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 4 diarrhea","valueDescription":"Life Threatening or Disabling Adverse Event Diarrhea","ValueMeaning":{"publicId":"4420608","version":"1","preferredName":"Life Threatening or Disabling Adverse Event Diarrhea","longName":"4420608","preferredDefinition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: Watery bowel movements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Life Threatening or Disabling Adverse Event","conceptCode":"C41337","definition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Diarrhea","conceptCode":"C2987","definition":"Watery bowel movements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-5203-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-521C-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 4 vomiting","valueDescription":"Life Threatening or Disabling Adverse Event Vomiting","ValueMeaning":{"publicId":"4420609","version":"1","preferredName":"Life Threatening or Disabling Adverse Event Vomiting","longName":"4420609","preferredDefinition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: Forceful ejection of the contents of the stomach through the mouth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Life Threatening or Disabling Adverse Event","conceptCode":"C41337","definition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Vomiting","conceptCode":"C3442","definition":"Forceful ejection of the contents of the stomach through the mouth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-5229-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-5242-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 4 nausea","valueDescription":"Life Threatening or Disabling Adverse Event Nausea","ValueMeaning":{"publicId":"4420610","version":"1","preferredName":"Life Threatening or Disabling Adverse Event Nausea","longName":"4420610","preferredDefinition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: Upper abdominal discomfort associated with an urge to vomit.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Life Threatening or Disabling Adverse Event","conceptCode":"C41337","definition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Nausea","conceptCode":"C3258","definition":"Upper abdominal discomfort associated with an urge to vomit.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-524F-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-5268-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Hematologic toxicity resulting in treatment delay of more than 14 days","valueDescription":"Hematologic toxicity resulting in treatment delay of more than 14 days","ValueMeaning":{"publicId":"4420611","version":"1","preferredName":"Hematologic toxicity resulting in treatment delay of more than 14 days","longName":"4420611","preferredDefinition":"Hematologic toxicity resulting in treatment delay of more than 14 days","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-5272-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-528B-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 3 thrombocytopenia in the presence of bleeding","valueDescription":"Severe Adverse Event Thrombocytopenia","ValueMeaning":{"publicId":"4420612","version":"1","preferredName":"Severe Adverse Event Thrombocytopenia","longName":"4420612","preferredDefinition":"An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.: A condition in which there is an abnormally small number of platelets in the circulating blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Severe Adverse Event","conceptCode":"C41340","definition":"An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Thrombocytopenia","conceptCode":"C3408","definition":"A laboratory test result indicating that there is an abnormally small number of platelets in the circulating blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF801890-5298-1EFA-E040-BB89AD434E8D","latestVersionIndicator":"Yes","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-52B1-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 4 anemia for more than 7 days","valueDescription":"Life Threatening or Disabling Adverse Event Anemia","ValueMeaning":{"publicId":"3607989","version":"1","preferredName":"Life Threatening or Disabling Adverse Event Anemia","longName":"3607989","preferredDefinition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.: A reduction in the number of red blood cells per cu mm, the amount of hemoglobin in 100 ml of blood, and the volume of packed red blood cells per 100 ml of blood. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Life Threatening or Disabling Adverse Event","conceptCode":"C41337","definition":"Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Anemia","conceptCode":"C2869","definition":"A reduction in the number of red blood cells, the amount of hemoglobin, and/or the volume of packed red blood cells. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBA4A7CC-86CA-5D6F-E040-BB89AD43026D","latestVersionIndicator":"Yes","beginDate":"2012-10-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-52C5-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 3-4 febrile neutropenia","valueDescription":"Grade 3-4 Febrile Neutropenia","ValueMeaning":{"publicId":"2636912","version":"1","preferredName":"Grade 3-4 Febrile Neutropenia","longName":"2636912","preferredDefinition":"Grade 3-4 Febrile Neutropenia","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FFA293A-BA94-17F5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-05-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF801890-52D9-1EFA-E040-BB89AD434E8D","beginDate":"2014-07-31","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-07-31","modifiedBy":"ONEDATA","dateModified":"2014-07-31","deletedIndicator":"No"},{"value":"Grade 3 headache for more than 7 days despite maximum supportive care measures","valueDescription":"Grade 3 headache for more than 7 days despite maximum supportive care measures","ValueMeaning":{"publicId":"4649510","version":"1","preferredName":"Grade 3 headache for more than 7 days despite maximum supportive care measures","longName":"4649510","preferredDefinition":"Grade 3 headache for more than 7 days despite maximum supportive care measures","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BE99D6A-49F7-D8FC-E050-BB89AD431BCB","latestVersionIndicator":"Yes","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BE99D6A-4A10-D8FC-E050-BB89AD431BCB","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"ONEDATA","dateModified":"2015-01-05","deletedIndicator":"No"},{"value":"Existing > Grade 2 hypertension for which additional anti-hypertensive therapy is needed and remains uncontrolled after 1 week despite maximum dosing of the additional anti-hypertensive therapy","valueDescription":"Existing > Grade 2 hypertension for which additional anti-hypertensive therapy is needed and remains uncontrolled after 1 week despite maximum dosing of the additional anti-hypertensive therapy","ValueMeaning":{"publicId":"4649511","version":"1","preferredName":"Existing > Grade 2 hypertension for which additional anti-hypertensive therapy is needed and remains uncontrolled after 1 week despite maximum dosing of the additional anti-hypertensive therapy","longName":"4649511","preferredDefinition":"Existing > Grade 2 hypertension for which additional anti-hypertensive therapy is needed and remains uncontrolled after 1 week despite maximum dosing of the additional anti-hypertensive therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BE99D6A-4A1A-D8FC-E050-BB89AD431BCB","latestVersionIndicator":"Yes","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BE99D6A-4A33-D8FC-E050-BB89AD431BCB","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"ONEDATA","dateModified":"2015-01-05","deletedIndicator":"No"},{"value":"Development of > Grade 2 asymptomatic hypertension remaining uncontrolled after 1 week of maximum dose of 2 anti-hypertensive agents","valueDescription":"Development of > Grade 2 asymptomatic hypertension remaining uncontrolled after 1 week of maximum dose of 2 anti-hypertensive agents","ValueMeaning":{"publicId":"4649512","version":"1","preferredName":"Development of > Grade 2 asymptomatic hypertension remaining uncontrolled after 1 week of maximum dose of 2 anti-hypertensive agents","longName":"4649512","preferredDefinition":"Development of > Grade 2 asymptomatic hypertension remaining uncontrolled after 1 week of maximum dose of 2 anti-hypertensive agents","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BE99D6A-4A3D-D8FC-E050-BB89AD431BCB","latestVersionIndicator":"Yes","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BE99D6A-4A56-D8FC-E050-BB89AD431BCB","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"ONEDATA","dateModified":"2015-01-05","deletedIndicator":"No"},{"value":"Grade 3-4 diarrhea occurring despite optimal medical management","valueDescription":"Grade 3-4 diarrhea occurring despite optimal medical management","ValueMeaning":{"publicId":"4649515","version":"1","preferredName":"Grade 3-4 diarrhea occurring despite optimal medical management","longName":"4649515","preferredDefinition":"Grade 3-4 diarrhea occurring despite optimal medical management","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BE99D6A-4AA6-D8FC-E050-BB89AD431BCB","latestVersionIndicator":"Yes","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BE99D6A-4ABF-D8FC-E050-BB89AD431BCB","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"ONEDATA","dateModified":"2015-01-05","deletedIndicator":"No"},{"value":"Symptomatic hypertension remaining uncontrolled after 1 week of maximum dose of 2 anti-hypertensive agents","valueDescription":"Symptomatic hypertension remaining uncontrolled after 1 week of maximum dose of 2 anti-hypertensive agents","ValueMeaning":{"publicId":"4649513","version":"1","preferredName":"Symptomatic hypertension remaining uncontrolled after 1 week of maximum dose of 2 anti-hypertensive agents","longName":"4649513","preferredDefinition":"Symptomatic hypertension remaining uncontrolled after 1 week of maximum dose of 2 anti-hypertensive agents","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BE99D6A-4A60-D8FC-E050-BB89AD431BCB","latestVersionIndicator":"Yes","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BE99D6A-4A79-D8FC-E050-BB89AD431BCB","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"ONEDATA","dateModified":"2015-01-05","deletedIndicator":"No"},{"value":"Grade 3-4 anorexia occurring despite optimal medical management","valueDescription":"Grade 3-4 anorexia occurring despite optimal medical management","ValueMeaning":{"publicId":"4649514","version":"1","preferredName":"Grade 3-4 anorexia occurring despite optimal medical management","longName":"4649514","preferredDefinition":"Grade 3-4 anorexia occurring despite optimal medical management","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BE99D6A-4A83-D8FC-E050-BB89AD431BCB","latestVersionIndicator":"Yes","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BE99D6A-4A9C-D8FC-E050-BB89AD431BCB","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"ONEDATA","dateModified":"2015-01-05","deletedIndicator":"No"},{"value":"Grade 3-4 vomiting occurring despite optimal medical management","valueDescription":"Grade 3-4 vomiting occurring despite optimal medical management","ValueMeaning":{"publicId":"4649516","version":"1","preferredName":"Grade 3-4 vomiting occurring despite optimal medical management","longName":"4649516","preferredDefinition":"Grade 3-4 vomiting occurring despite optimal medical management","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BE99D6A-4AC9-D8FC-E050-BB89AD431BCB","latestVersionIndicator":"Yes","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BE99D6A-4AE2-D8FC-E050-BB89AD431BCB","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"ONEDATA","dateModified":"2015-01-05","deletedIndicator":"No"},{"value":"Grade 3-4 nausea occurring despite optimal medical management","valueDescription":"Grade 3-4 nausea occurring despite optimal medical management","ValueMeaning":{"publicId":"4649517","version":"1","preferredName":"Grade 3-4 nausea occurring despite optimal medical management","longName":"4649517","preferredDefinition":"Grade 3-4 nausea occurring despite optimal medical management","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BE99D6A-4AEC-D8FC-E050-BB89AD431BCB","latestVersionIndicator":"Yes","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BE99D6A-4B05-D8FC-E050-BB89AD431BCB","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"ONEDATA","dateModified":"2015-01-05","deletedIndicator":"No"},{"value":"Grade 4 neutropenia for more than 7 days","valueDescription":"Grade 4 neutropenia for more than 7 days","ValueMeaning":{"publicId":"4649518","version":"1","preferredName":"Grade 4 neutropenia for more than 7 days","longName":"4649518","preferredDefinition":"Grade 4 neutropenia for more than 7 days","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BE99D6A-4B0F-D8FC-E050-BB89AD431BCB","latestVersionIndicator":"Yes","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BE99D6A-4B28-D8FC-E050-BB89AD431BCB","beginDate":"2015-01-05","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-05","modifiedBy":"ONEDATA","dateModified":"2015-01-05","deletedIndicator":"No"},{"value":"Other Myelosuppression","valueDescription":"Other Myelosuppression","ValueMeaning":{"publicId":"5021067","version":"1","preferredName":"Other Myelosuppression","longName":"5021067","preferredDefinition":"Other Myelosuppression","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2009FD9F-48F8-D698-E050-BB89AD432FBA","latestVersionIndicator":"Yes","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2009FD9F-4911-D698-E050-BB89AD432FBA","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"ONEDATA","dateModified":"2015-09-18","deletedIndicator":"No"},{"value":"Grade 3 AST elevation","valueDescription":"Grade 3 AST elevation","ValueMeaning":{"publicId":"5021068","version":"1","preferredName":"Grade 3 AST elevation","longName":"5021068","preferredDefinition":"Grade 3 AST elevation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2009FD9F-491B-D698-E050-BB89AD432FBA","latestVersionIndicator":"Yes","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2009FD9F-4934-D698-E050-BB89AD432FBA","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"ONEDATA","dateModified":"2015-09-18","deletedIndicator":"No"},{"value":"Grade 3 ALT elevation","valueDescription":"Grade 3 ALT elevation","ValueMeaning":{"publicId":"5021069","version":"1","preferredName":"Grade 3 ALT elevation","longName":"5021069","preferredDefinition":"Grade 3 ALT elevation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2009FD9F-493E-D698-E050-BB89AD432FBA","latestVersionIndicator":"Yes","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2009FD9F-4957-D698-E050-BB89AD432FBA","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"ONEDATA","dateModified":"2015-09-18","deletedIndicator":"No"},{"value":"Grade 3 or greater bowel perforation","valueDescription":"Grade 3 or greater bowel perforation","ValueMeaning":{"publicId":"5021070","version":"1","preferredName":"Grade 3 or greater bowel perforation","longName":"5021070","preferredDefinition":"Grade 3 or greater bowel perforation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2009FD9F-4961-D698-E050-BB89AD432FBA","latestVersionIndicator":"Yes","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2009FD9F-497A-D698-E050-BB89AD432FBA","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"ONEDATA","dateModified":"2015-09-18","deletedIndicator":"No"},{"value":"Grade 3 or greater colitis","valueDescription":"Grade 3 or greater colitis","ValueMeaning":{"publicId":"5021071","version":"1","preferredName":"Grade 3 or greater colitis","longName":"5021071","preferredDefinition":"Grade 3 or greater colitis","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2009FD9F-4984-D698-E050-BB89AD432FBA","latestVersionIndicator":"Yes","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2009FD9F-499D-D698-E050-BB89AD432FBA","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"ONEDATA","dateModified":"2015-09-18","deletedIndicator":"No"},{"value":"Grade 3-4 pneumonitis","valueDescription":"Grade 3-4 pneumonitis","ValueMeaning":{"publicId":"5021072","version":"1","preferredName":"Grade 3-4 pneumonitis","longName":"5021072","preferredDefinition":"Grade 3-4 pneumonitis","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2009FD9F-49A7-D698-E050-BB89AD432FBA","latestVersionIndicator":"Yes","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2009FD9F-49C0-D698-E050-BB89AD432FBA","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"ONEDATA","dateModified":"2015-09-18","deletedIndicator":"No"},{"value":"Grade 3-4 immune related adverse event","valueDescription":"Grade 3-4 immune related adverse event","ValueMeaning":{"publicId":"5021073","version":"1","preferredName":"Grade 3-4 immune related adverse event","longName":"5021073","preferredDefinition":"Grade 3-4 immune related adverse event","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2009FD9F-49CA-D698-E050-BB89AD432FBA","latestVersionIndicator":"Yes","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2009FD9F-49E3-D698-E050-BB89AD432FBA","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"ONEDATA","dateModified":"2015-09-18","deletedIndicator":"No"},{"value":"Grade 3-4 hypersensitivity reaction","valueDescription":"Grade 3-4 hypersensitivity reaction","ValueMeaning":{"publicId":"5021074","version":"1","preferredName":"Grade 3-4 hypersensitivity reaction","longName":"5021074","preferredDefinition":"Grade 3-4 hypersensitivity reaction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2009FD9F-49ED-D698-E050-BB89AD432FBA","latestVersionIndicator":"Yes","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2009FD9F-4A06-D698-E050-BB89AD432FBA","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"ONEDATA","dateModified":"2015-09-18","deletedIndicator":"No"},{"value":"Grade 3-4 non-hematologic toxicity","valueDescription":"Grade 3-4 non-hematologic toxicity","ValueMeaning":{"publicId":"5021075","version":"1","preferredName":"Grade 3-4 non-hematologic toxicity","longName":"5021075","preferredDefinition":"Grade 3-4 non-hematologic toxicity","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2009FD9F-4A10-D698-E050-BB89AD432FBA","latestVersionIndicator":"Yes","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2009FD9F-4A29-D698-E050-BB89AD432FBA","beginDate":"2015-09-18","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-09-18","modifiedBy":"ONEDATA","dateModified":"2015-09-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2453188","version":"1","preferredName":"Grade","preferredDefinition":"A position on a scale of intensity or amount or quality.","longName":"C48309","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"0DDD1E7C-BBFA-66D1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-28","modifiedBy":"ONEDATA","dateModified":"2006-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBA4A7CC-868B-5D6F-E040-BB89AD43026D","latestVersionIndicator":"Yes","beginDate":"2012-10-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-10-09","modifiedBy":"ROUILLAS","dateModified":"2015-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"}],"ReferenceDocuments":[{"name":"Worst grade","type":"Preferred Question Text","description":"Worst grade","url":null,"context":"CTEP"},{"name":"ECOG CRF Text 1","type":"Alternate Question Text","description":"Dose Limiting Toxicity","url":null,"context":"ECOG-ACRIN"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBA3F33F-D874-1BE1-E040-BB89AD4377ED","latestVersionIndicator":"Yes","beginDate":"2012-10-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-10-09","modifiedBy":"ROUILLAS","dateModified":"2014-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}